TWSTTwist Bioscience Corporation

Twist Bioscience Corporation (NASDAQ: TWST) | Price: $97.36 | Today's Change: -20.58%

---

What Happened

Twist Bioscience filed an 8-K with the SEC on November 12, 2026, disclosing its fiscal third-quarter 2026 financial results under Items 2.02 and 9.01. The company reported a net loss of $50,532,000 for the quarter, translating to a loss per share of $0.85 on both a basic and diluted basis. More notably, the operating loss came in at $106,325,000 — a figure that underscores the significant gap between revenues and total operating costs that remains a defining feature of Twist's financial profile.

---

Why It Matters

The scale of the operating loss — over $106 million in a single quarter — is a critical data point for investors assessing the pace and credibility of Twist's path toward profitability. While the net loss of $50.5 million is narrower than the operating loss (reflecting non-operating items such as interest or other income not broken out in the structured data provided), the operating loss figure itself signals that core business expenses continue to significantly outpace revenue generation. The stock's sharp single-day decline of 20.58% to $97.36 reflects the market's immediate and negative reaction to these results. This follows StockWatch's existing initiating coverage on TWST, which provides broader context on the company's strategic positioning.

---

Analysis

The $106.3 million operating loss in Q3 FY2026 is the number that demands the most attention. The divergence between the operating loss and the net loss of $50.5 million suggests meaningful non-operating income — likely interest income from Twist's cash reserves, which the company has historically relied upon to partially offset operational cash burn. However, that buffer does not change the underlying operational reality: the core business is still consuming capital at a substantial rate.

The -20.58% intraday move is an unusually large single-session reaction, suggesting the results either missed market expectations materially or that forward guidance (if provided in the accompanying materials) disappointed investors. The structured XBRL data alone does not capture revenue figures or guidance language, so readers should consult the full earnings release and any accompanying conference call transcript for those details.

Key items to watch going forward:

• Whether operating losses show a sequential narrowing trend, which would signal improving operational leverage
• The trajectory of Twist's cash and liquidity position, given the sustained magnitude of operating cash consumption
• Any updated commentary on synthetic biology demand trends and customer pipeline development
• How management frames the timeline to operating breakeven

The gap between the current trading price of $97.36 and the levels implied by prior coverage reflects how sharply a single earnings report can reshape near-term sentiment around a pre-profitability growth company.

---

Disclaimer

This report is a news and informational summary based solely on data contained in Twist Bioscience's SEC filing dated November 12, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research recommendation of any kind. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on TWST, published 2026-09-16. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-12. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000053/twist-20261112.htm